⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2443660 | 0.90 | — | — | |
| SCHEMBL19335431 | 0.82 | — | — | |
| SCHEMBL19152521 | 0.77 | — | — | |
| SCHEMBL18799890 | 0.73 | — | — | |
| SCHEMBL7066357 | 0.73 | — | — | |
| SCHEMBL15916667 | 0.72 | ANPEP (0.40) | — | |
| SCHEMBL16710147 | 0.72 | — | — | |
| SCHEMBL5199147 | 0.69 | ANPEP (0.38) | — | |
| SCHEMBL22652465 | 0.67 | — | — | |
| SCHEMBL20384378 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107371-A2 | INDOLYL-PYRIDINONES AND RELATED COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250326721-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4577549-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | Iambic Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250197375-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2009067493-A2 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1385506-B1 | ACYLATED PIPERIDINE DERIVATES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080287663-A1 | Process For Production Of 4-Biphenylyazetidin-2-Ones | MICROBIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2008061238-A2 | PROCESSES FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008057948-A2 | PROCESSES FOR PRODUCTION OF DIPHENYLYLAZETIDIN-2-ONES AND RELATED COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |